# Peptides and Ehlers-Danlos syndrome · PepVault guides

Source: https://pepvault.app/guides/peptides-and-ehlers-danlos

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [Recovery](https://pepvault.app/guides#recovery)

# Peptides and Ehlers-Danlos syndrome: what to know before trying one

Reviewed November 2026 31 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

No study has tested BPC-157, TB-500, GHK-Cu or collagen peptides in EDS. Who the healing studies included, why vascular EDS matters most, and who decides.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 31
- **Questions:** 9
- **Compounds:** 6

## The short answer

No study has tested BPC-157, TB-500, GHK-Cu or collagen peptides in people with Ehlers-Danlos syndrome: a November 2026 search of PubMed and ClinicalTrials.gov found none. Their healing data come from rats and from people without EDS, whose collagen genes work normally. The type matters most: in vascular EDS, arteries can tear, so any new compound is a decision for the vascular EDS team.

Every number checked at its primary source · Nov 20, 2026 · [31 sources](https://pepvault.app/guides/peptides-and-ehlers-danlos#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** No study has tested BPC-157, TB-500, GHK-Cu, collagen peptides or a GLP-1 drug in EDS; their data come from animals and from people without EDS, and the randomized drug trials in EDS are in the vascular type.

## Has any peptide been studied in Ehlers-Danlos syndrome?

Not the ones people ask about. On November 20, 2026 we searched PubMed for each compound together with Ehlers-Danlos or hypermobility, and ClinicalTrials.gov for trials that pair them[1](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-1) [2](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-2). PubMed holds 9,682 records on Ehlers-Danlos syndrome (EDS) or hypermobility, and ClinicalTrials.gov lists 101 studies of EDS. The compounds below appear in none of them.

| Compound | PubMed records with EDS or hypermobility | Trials registered in EDS or hypermobility |
| --- | --- | --- |
| BPC-157 | 0 (one hit, a 1987 paper on another syndrome) | 0 |
| TB-500 or thymosin beta-4 | 0 | 0 |
| GHK-Cu (copper peptide) | 0 | 0 |
| Collagen peptides as a supplement | 0 (a few lab papers on collagen in EDS; none tested a supplement) | 0 |
| Semaglutide, tirzepatide or liraglutide | 0 | 0 |

Two peptides have been given to people with EDS, and neither is one of these. In Copenhagen, 5 people with classical EDS and 10 matched controls had IGF-I, a growth factor, injected into one kneecap tendon and saline into the other. The EDS tendons built protein at a normal rate to begin with, and IGF-I raised that rate in the EDS group but not in the controls[3](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-3). A trial of oxytocin, a small peptide hormone, for pain in hypermobile EDS closed after enrolling 2 people, with 1 completing both arms[4](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-4).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault records the site with each injected dose and keeps a side-effect log with a severity and a date, so a bruise that keeps coming back at one spot shows up in your own record.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What is Ehlers-Danlos syndrome, and why does the type matter?

EDS is a group of inherited conditions of connective tissue, the tissue that holds skin, joints and blood vessels together. The 2017 international classification names 13 types, marked by loose joints, stretchy skin and fragile tissue. Most are caused by a change in a collagen gene or in a gene for an enzyme that finishes collagen, and all but one are confirmed by a genetic test[5](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-5).

The exception is the hypermobile type (hEDS), diagnosed from its signs because, in most people with it, no cause has been found[5](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-5) [6](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-6). Hypermobile and classical EDS are the most common, and together all the types affect at least 1 in 5,000 people[6](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-6). Classical EDS comes mostly from the COL5A1 or COL5A2 genes, with wounds that split open easily and skin that bruises easily[6](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-6). Vascular EDS (vEDS) comes from COL3A1, the gene for type III collagen, a main protein of artery walls and hollow organs, and affects about 1 in 50,000 to 1 in 200,000 people[7](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-7).

- **Hypermobile EDS:** no known gene in most people; joint pain, instability and the overlap conditions further down.
- **Classical EDS:** type V collagen; fragile, stretchy skin, wounds that split, easy bruising.
- **Vascular EDS:** type III collagen; arteries, bowel and uterus can tear.

## Why does vascular EDS change everything?

Because the risk is in the arteries, not the joints. In 220 people with vEDS and 199 affected relatives, more than 80% of the 220 had a major complication by age 40, most deaths came from a torn artery, and median survival was 48 years[8](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-8). That is why the trials in vEDS test blood-pressure drugs, not healing compounds.

| Trial | Who | What was given | Arterial events |
| --- | --- | --- | --- |
| BBEST, France and Belgium, 2010[9](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-9) | 53 people with vEDS, followed about 4 years | Celiprolol, a beta blocker, or no treatment | 20% on celiprolol against 50% without; stopped early for benefit |
| ARCADE, France, 2025[10](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-10) | 57 people with vEDS already on celiprolol, for 2 years | Irbesartan, a blood-pressure drug, or placebo | 27.6% on irbesartan against 53.6% on placebo (arterial events or new lesions on scans) |
| DiSCOVER, US[11](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-11) | 150 planned | Celiprolol or placebo | Recruiting; estimated to finish in 2029 |

The international care guidance for vEDS asks for a genetic diagnosis, a specialist team, blood pressure kept in the normal range, yearly scans of the arteries and a daily life arranged to avoid injury[7](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-7). No peptide has been tested in vEDS. In chick embryos, rat muscle and human cells, BPC-157 grows new blood vessels[31](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-31), and no one has studied what it does to arteries built from altered type III collagen. With vEDS, a new compound is a question for that team before anything else.

**When to get help** With vascular EDS, an artery or the bowel can tear without warning[6](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-6) [8](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-8): keep the emergency care plan your team gives you (the vascular EDS passport) with you, and show it to any emergency team[7](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-7).

## With this guide

### BPC-157

- [BPC-157: the full reference](https://pepvault.app/peptides/bpc-157)
- [BPC-157 dose guide](https://pepvault.app/lab/dosage/bpc-157)

### TB-500

- [TB-500: the full reference](https://pepvault.app/peptides/tb-500)
- [TB-500 dose guide](https://pepvault.app/lab/dosage/tb-500)

### Mixing charts

- [BPC-157 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-5mg)
- [BPC-157 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-10mg)
- [TB-500 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-5mg)
- [TB-500 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-10mg)
- [GHK-Cu 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-10mg)
- [GHK-Cu 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-50mg)
- [GHK-Cu 100 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-100mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)

### Studies

- [BPC-157: 10 of 12 women reported full interstitial cystitis relief](https://pepvault.app/research/bpc-157-lee-2024)
- [BPC-157: 14 of 16 reported knee pain relief in a chart review](https://pepvault.app/research/bpc-157-lee-2021)
- [BPC-157: non-significant tendon gains in rats; TB-500 did better](https://pepvault.app/research/bpc-157-bicer-2026)
- [All 14 studies](https://pepvault.app/research#bpc-157)
- [Thymosin beta-4: no overall infarct area cut in 96 STEMI patients](https://pepvault.app/research/thymosin-beta-4-zhang-2025)
- [TB-500 on venous ulcers: safety comparable to placebo in Phase 2](https://pepvault.app/research/tb-500-guarnera-2010)
- [All 9 studies](https://pepvault.app/research#tb-500)

### Compared with

- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [BPC-157 vs TB-500](https://pepvault.app/peptides/compare/bpc-157-vs-tb-500)
- [KPV vs BPC-157](https://pepvault.app/peptides/compare/kpv-vs-bpc-157)
- [GHK-Cu vs BPC-157](https://pepvault.app/peptides/compare/ghk-cu-vs-bpc-157)
- [BPC-157 vs Thymosin Beta-4](https://pepvault.app/peptides/compare/bpc-157-vs-thymosin-beta-4)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Recovery path

- [BPC-157: the human data we have](https://pepvault.app/guides/bpc-157-human-data)
- [BPC-157 and TB-500 together](https://pepvault.app/guides/bpc-157-and-tb-500)
- [BPC-157 oral, nasal or injected: what each route has behind it](https://pepvault.app/guides/bpc-157-oral-nasal-injected)
- [BPC-157 vs KPV: how they differ and what each has behind it](https://pepvault.app/guides/bpc-157-vs-kpv)
- [TB-500 vs TB4 (thymosin beta-4): are they the same thing?](https://pepvault.app/guides/tb-500-vs-thymosin-beta-4)
- [KLOW and GLOW: what's in each blend and what's known](https://pepvault.app/guides/klow-and-glow)
- [Do oral peptides work? Which peptides survive the gut](https://pepvault.app/guides/oral-peptides)
- [Peptides and drug tests: what WADA and the NCAA ban](https://pepvault.app/guides/peptides-and-drug-tests)
- [When to take BPC-157: morning, night, or around training?](https://pepvault.app/guides/when-to-take-bpc-157)
- [How to mix BPC-157 and TB-500](https://pepvault.app/guides/how-to-mix-bpc-157-and-tb-500)
- [What is LL-37, and what do the studies show?](https://pepvault.app/guides/ll-37-what-the-studies-show)
- [What is VIP peptide? What the studies show](https://pepvault.app/guides/vip-peptide-what-the-studies-show)
- [BPC-157 for the gut: what the studies show](https://pepvault.app/guides/bpc-157-for-the-gut)
- [How long to take BPC-157, and does it need cycling?](https://pepvault.app/guides/how-long-to-take-bpc-157)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

## Who were BPC-157, TB-500, GHK-Cu and collagen tested in?

In rats, and in people whose collagen is normal. None of these studies was designed for EDS, and none reports enrolling anyone with it.

| Compound | Animal work | People studied | People with EDS |
| --- | --- | --- | --- |
| BPC-157 | Rats; in a 2026 study of 32 rats with repaired Achilles tendons, it raised tendon strength, but not significantly[15](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-15) | 30 in three pilots: 16 with knee pain, 12 women with bladder pain, 2 healthy adults given it by IV[12](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-12) [13](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-13) [14](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-14) | None |
| TB-500 or thymosin beta-4 | In the same rat study, TB-500 made repaired tendons significantly stronger[15](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-15) | 40 healthy volunteers in a placebo-controlled IV safety study; 73 people with leg ulcers treated on the skin[16](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-16) [17](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-17) | None |
| GHK-Cu | Cell and animal wound studies (pepvault.app/guides/ghk-cu-skin-and-hair) | 13 people after laser skin resurfacing, with no difference on blinded measures; 86 with leg ulcers, where a GHK-Cu cream did no better than placebo[18](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-18) [19](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-19) | None |
| Collagen peptides | Rodent and cell work on bone[21](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-21) | 139 athletes with knee pain; 131 women past menopause; 20 people with Achilles tendon pain; 2,534 healthy adults in 35 skin trials[20](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-20) [21](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-21) [22](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-22) [23](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-23) | None |

The collagen trials are the strongest set here: placebo-controlled, with modest gains on knee pain in sport, bone density and Achilles rehab[20](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-20) [21](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-21) [22](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-22). The full read is in pepvault.app/guides/bpc-157-human-data, pepvault.app/guides/bpc-157-and-tb-500 and pepvault.app/guides/collagen-vs-research-peptides, and each compound's library page (pepvault.app/peptides/bpc-157, pepvault.app/peptides/tb-500, pepvault.app/peptides/ghk-cu, pepvault.app/peptides/collagen-peptides) has its side effects.

## Can a healing peptide fix a collagen gene?

No compound changes the gene, and that is the heart of the gap. In the rat studies, the tendon cells carried normal collagen genes, so a repair signal sped up a process that builds normal tissue[15](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-15). In classical or vascular EDS, the altered gene is still there, and no study shows whether a repair signal builds normal tissue on top of it. Collagen peptides supply raw amino acids (pepvault.app/glossary/amino-acid); they do not change the gene's instructions either.

The Copenhagen IGF-I study is the one test of the idea in EDS. Its classical EDS patients made tendon protein at a normal rate, and their tendons answered a growth signal more strongly than the controls' did[3](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-3). It measured six hours of protein building in 5 people. It did not measure whether the new tissue was normal or the tendon stronger. In hEDS, where no gene is known for most people, there is no study of what a repair signal acts on.

## What should someone with EDS watch for with injections?

Bruising and numbing. Easy bruising runs through the EDS types, and fragile skin is common[6](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-6). A small needle under the skin (pepvault.app/glossary/subcutaneous) can leave a bigger bruise in EDS than in most people, which is one more reason to move each shot to a new spot (pepvault.app/guides/injection-site-rotation).

Many people with EDS also report that local anaesthetics work poorly. A 2005 report described local anaesthetic failure in joint hypermobility, and Vanderbilt is now measuring it against healthy volunteers in a planned 230 people, because the reports have never had objective data[24](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-24) [25](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-25).

<!--promo-->

PepVault records the site with each injected dose and keeps a side-effect log with a severity and a date, so a bruise that keeps coming back at one spot shows up in your own record. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-peptides-and-ehlers-danlos-inline&mt=8)

<!--/promo-->

## Do mast cell problems, POTS and gut symptoms change the picture?

They change what to ask. A 2026 meta-analysis of 19 studies and 17,455 people with hEDS or hypermobility found that 65.3% had at least one chronic gut symptom, 41.3% had reflux disease, 35.9% had orthostatic intolerance (feeling faint or unwell when standing) and 21.9% had POTS, a heart rate that races on standing[26](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-26). Mast cells, immune cells that release histamine, have been proposed as part of the picture[27](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-27), but a 2026 Mayo Clinic report found no evidence that mast cell activation syndrome is more common in POTS or hEDS[28](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-28).

This matters most for GLP-1 drugs (pepvault.app/glossary/glp-1), the most prescribed peptides. Wegovy and Zepbound both slow how fast the stomach empties, and both labels say they are not recommended in severe gastroparesis, a stomach that empties far too slowly[29](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-29) [30](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-30). Wegovy raises resting heart rate by 1 to 4 beats a minute on average and Zepbound by 1 to 3[29](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-29) [30](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-30); in Wegovy's weight trials, 26% on the drug had a rise of 20 or more at some visit, against 16% on placebo[29](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-29). No study has tested a GLP-1 drug in EDS[1](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-1). With POTS or slow stomach emptying, those two label lines are the ones to raise with the prescriber (pepvault.app/peptides/semaglutide, pepvault.app/peptides/tirzepatide).

## What do people with EDS report?

**Commonly reported:** people with hEDS most often bring up BPC-157 and TB-500 for joint and tendon pain, and GHK-Cu or collagen for skin; bruising at injection sites and numbing that wears off fast are frequent complaints, and many say their symptoms swing so much from week to week that a few weeks on anything is hard to read.

That last point is why notes from before and after help: pain and fatigue in hEDS rise and fall on their own.

## Who decides, and what do you bring to that conversation?

The clinician who manages your EDS decides, and for vascular EDS, the vascular team. What these studies give that conversation is what was tested, and in whom.

1. Know your type. Bring the genetic result if you have one; a vascular or classical result changes the conversation more than any study here[5](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-5) [7](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-7).
2. Name the compound and how it would be taken: by mouth, on the skin or by injection under the skin.
3. Say plainly what the evidence is: animal studies and small human pilots in people without EDS, and no study in EDS[1](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-1) [2](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-2).
4. Raise bruising, slow-healing skin and numbing that fails, if you have them, before any injection.
5. If a GLP-1 drug is on the table, raise POTS, a fast heart rate or slow stomach emptying, because both labels speak to them[29](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-29) [30](https://pepvault.app/guides/peptides-and-ehlers-danlos#source-30).
6. Agree on what you will track and when you will look at it together.

<!--promo-->

PepVault's doctor's report gathers your doses, injection sites and side effects for a chosen protocol on one page, ready to show the clinician who manages your EDS. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-peptides-and-ehlers-danlos-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. PubMed searches run November 20, 2026: each compound AND (ehlers-danlos[tiab] OR "Ehlers-Danlos Syndrome"[MeSH] OR hypermobil\*[tiab]); 9,682 records for that EDS term alone. [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=%28ehlers-danlos%5Btiab%5D+OR+%22Ehlers-Danlos+Syndrome%22%5BMeSH%5D+OR+hypermobil*%5Btiab%5D%29)
2. ClinicalTrials.gov searches run November 20, 2026: condition Ehlers-Danlos (101 studies) or hypermobility (116 studies), with each compound as the intervention (0 for each). [clinicaltrials.gov](https://clinicaltrials.gov/search?cond=Ehlers-Danlos)
3. Nielsen RH et al. Tendon protein synthesis rate in classic Ehlers-Danlos patients can be stimulated with insulin-like growth factor-I. J Appl Physiol. 2014. [PubMed 25103963](https://pubmed.ncbi.nlm.nih.gov/25103963/)
4. ClinicalTrials.gov NCT05405257. Oxytocin treatment for chronic pain in hypermobile Ehlers-Danlos syndrome. Baylor College of Medicine. Terminated. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05405257)
5. Malfait F et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. [PubMed 28306229](https://pubmed.ncbi.nlm.nih.gov/28306229/)
6. MedlinePlus Genetics. Ehlers-Danlos syndrome. U.S. National Library of Medicine. Last updated July 29, 2022. [medlineplus.gov](https://medlineplus.gov/genetics/condition/ehlers-danlos-syndrome/)
7. Byers PH et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017. [PubMed 28306228](https://pubmed.ncbi.nlm.nih.gov/28306228/)
8. Pepin M et al. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000. [PubMed 10706896](https://pubmed.ncbi.nlm.nih.gov/10706896/)
9. Ong KT et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010. [PubMed 20825986](https://pubmed.ncbi.nlm.nih.gov/20825986/)
10. Jeunemaitre X et al. Efficacy of irbesartan in celiprolol-treated patients with vascular Ehlers-Danlos syndrome. Circulation. 2025. [PubMed 39906986](https://pubmed.ncbi.nlm.nih.gov/39906986/)
11. ClinicalTrials.gov NCT05432466. Celiprolol compared with placebo in vascular Ehlers-Danlos syndrome (DiSCOVER). Acer Therapeutics. Recruiting. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05432466)
12. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. [PubMed 34324435](https://pubmed.ncbi.nlm.nih.gov/34324435/)
13. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. [PubMed 39325560](https://pubmed.ncbi.nlm.nih.gov/39325560/)
14. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. [PubMed 40131143](https://pubmed.ncbi.nlm.nih.gov/40131143/)
15. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026. [PubMed 42542926](https://pubmed.ncbi.nlm.nih.gov/42542926/)
16. Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. [PubMed 20536472](https://pubmed.ncbi.nlm.nih.gov/20536472/)
17. Guarnera G et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. [PubMed 20536470](https://pubmed.ncbi.nlm.nih.gov/20536470/)
18. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. [PubMed 16847171](https://pubmed.ncbi.nlm.nih.gov/16847171/)
19. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. [PubMed 1495150](https://pubmed.ncbi.nlm.nih.gov/1495150/)
20. Zdzieblik D et al. Improvement of activity-related knee joint discomfort following supplementation of specific collagen peptides. Appl Physiol Nutr Metab. 2017. [PubMed 28177710](https://pubmed.ncbi.nlm.nih.gov/28177710/)
21. König D et al. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women: a randomized controlled study. Nutrients. 2018. [PubMed 29337906](https://pubmed.ncbi.nlm.nih.gov/29337906/)
22. Praet SFE et al. Oral supplementation of specific collagen peptides combined with calf-strengthening exercises enhances function and reduces pain in Achilles tendinopathy patients. Nutrients. 2019. [PubMed 30609761](https://pubmed.ncbi.nlm.nih.gov/30609761/)
23. Batool A et al. Oral collagen peptides and skin rejuvenation: a systematic review and an updated meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2026. [PubMed 43047141](https://pubmed.ncbi.nlm.nih.gov/43047141/)
24. Hakim AJ et al. Local anaesthetic failure in joint hypermobility syndrome. J R Soc Med. 2005. [PubMed 15684369](https://pubmed.ncbi.nlm.nih.gov/15684369/)
25. ClinicalTrials.gov NCT04036305. Local anesthetic response in Ehlers-Danlos syndrome (EDS) and healthy volunteers. Vanderbilt University Medical Center. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04036305)
26. Kulin D et al. Meta-analysis: chronic gastrointestinal symptoms and comorbidities in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Aliment Pharmacol Ther. 2026. [PubMed 42437376](https://pubmed.ncbi.nlm.nih.gov/42437376/)
27. Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017. [PubMed 28261938](https://pubmed.ncbi.nlm.nih.gov/28261938/)
28. Valdez JA et al. Lack of evidence for increased mast cell activation syndrome prevalence in postural orthostatic tachycardia syndrome and/or hypermobile Ehlers-Danlos syndrome. J Allergy Clin Immunol Pract. 2026. [PubMed 42595300](https://pubmed.ncbi.nlm.nih.gov/42595300/)
29. Wegovy (semaglutide) prescribing information, sections 5.6, 5.9 and 7.2. Novo Nordisk. DailyMed, version 19, June 30, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
30. Zepbound (tirzepatide) prescribing information, sections 5.2, 6.1 and 7.2. Eli Lilly. DailyMed, version 40, September 2, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
31. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. [PubMed 27847966](https://pubmed.ncbi.nlm.nih.gov/27847966/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide

Guide · Skin and longevity

### [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)

What GHK-Cu has shown in people for skin and hair: the serum and laser trials, the hair studies, what is lab-only, and what injecting it has never tested.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [BPC-157 Studied range: 200–500 mcg](https://pepvault.app/peptides/bpc-157)
- [TB-500 Studied range: 1–2.5 mg](https://pepvault.app/peptides/tb-500)
- [GHK-Cu Studied range: 1–2 mg](https://pepvault.app/peptides/ghk-cu)
- [Collagen Peptides Studied range: 5–15 g](https://pepvault.app/peptides/collagen-peptides)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · Recovery

  ### [BPC-157: the human data we have](https://pepvault.app/guides/bpc-157-human-data)

  Every published human study of BPC-157: the knee pain, bladder pain and IV safety pilots, what each found, the trials now registered, and how it works.

  Read the guide
- Guide · Stacks

  ### [BPC-157 and TB-500 together](https://pepvault.app/guides/bpc-157-and-tb-500)

  BPC-157 and TB-500 together: what the one controlled study of the pair found, the seven patients given both, how each peptide works and what users report.

  Read the guide
- Guide · The science

  ### [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)

  Collagen peptides are food protein eaten by the gram; BPC-157 and GHK-Cu are exact chains used in milligrams. One table, then collagen's skin and joint trials.

  Read the guide
- Guide · Getting started

  ### [Injection site rotation: a plan for daily, weekly and twice-daily shots](https://pepvault.app/guides/injection-site-rotation)

  How to rotate injection sites: a zone plan for weekly GLP-1, daily and twice-daily shots, how long a spot rests, and how to check a site for lumps by touch.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### BPC-157

- [BPC-157: the full reference](https://pepvault.app/peptides/bpc-157)
- [BPC-157 dose guide](https://pepvault.app/lab/dosage/bpc-157)

### TB-500

- [TB-500: the full reference](https://pepvault.app/peptides/tb-500)
- [TB-500 dose guide](https://pepvault.app/lab/dosage/tb-500)

### Mixing charts

- [BPC-157 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-5mg)
- [BPC-157 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-10mg)
- [TB-500 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-5mg)
- [TB-500 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-10mg)
- [GHK-Cu 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-10mg)
- [GHK-Cu 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-50mg)
- [GHK-Cu 100 mg vial](https://pepvault.app/tools/reconstitution-calculator/ghk-cu-100mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)

### Studies

- [BPC-157: 10 of 12 women reported full interstitial cystitis relief](https://pepvault.app/research/bpc-157-lee-2024)
- [BPC-157: 14 of 16 reported knee pain relief in a chart review](https://pepvault.app/research/bpc-157-lee-2021)
- [BPC-157: non-significant tendon gains in rats; TB-500 did better](https://pepvault.app/research/bpc-157-bicer-2026)
- [All 14 studies](https://pepvault.app/research#bpc-157)
- [Thymosin beta-4: no overall infarct area cut in 96 STEMI patients](https://pepvault.app/research/thymosin-beta-4-zhang-2025)
- [TB-500 on venous ulcers: safety comparable to placebo in Phase 2](https://pepvault.app/research/tb-500-guarnera-2010)
- [All 9 studies](https://pepvault.app/research#tb-500)

### Compared with

- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [BPC-157 vs TB-500](https://pepvault.app/peptides/compare/bpc-157-vs-tb-500)
- [KPV vs BPC-157](https://pepvault.app/peptides/compare/kpv-vs-bpc-157)
- [GHK-Cu vs BPC-157](https://pepvault.app/peptides/compare/ghk-cu-vs-bpc-157)
- [BPC-157 vs Thymosin Beta-4](https://pepvault.app/peptides/compare/bpc-157-vs-thymosin-beta-4)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Recovery path

- [BPC-157: the human data we have](https://pepvault.app/guides/bpc-157-human-data)
- [BPC-157 and TB-500 together](https://pepvault.app/guides/bpc-157-and-tb-500)
- [BPC-157 oral, nasal or injected: what each route has behind it](https://pepvault.app/guides/bpc-157-oral-nasal-injected)
- [BPC-157 vs KPV: how they differ and what each has behind it](https://pepvault.app/guides/bpc-157-vs-kpv)
- [TB-500 vs TB4 (thymosin beta-4): are they the same thing?](https://pepvault.app/guides/tb-500-vs-thymosin-beta-4)
- [KLOW and GLOW: what's in each blend and what's known](https://pepvault.app/guides/klow-and-glow)
- [Do oral peptides work? Which peptides survive the gut](https://pepvault.app/guides/oral-peptides)
- [Peptides and drug tests: what WADA and the NCAA ban](https://pepvault.app/guides/peptides-and-drug-tests)
- [When to take BPC-157: morning, night, or around training?](https://pepvault.app/guides/when-to-take-bpc-157)
- [How to mix BPC-157 and TB-500](https://pepvault.app/guides/how-to-mix-bpc-157-and-tb-500)
- [What is LL-37, and what do the studies show?](https://pepvault.app/guides/ll-37-what-the-studies-show)
- [What is VIP peptide? What the studies show](https://pepvault.app/guides/vip-peptide-what-the-studies-show)
- [BPC-157 for the gut: what the studies show](https://pepvault.app/guides/bpc-157-for-the-gut)
- [How long to take BPC-157, and does it need cycling?](https://pepvault.app/guides/how-long-to-take-bpc-157)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
